Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Healthcare
Industry
Healthcare Plans
Country
United States
Market cap
10.0B USD
Enterprise value
2.5B USD
Full-time employees
2,305
Overall health
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 2.47 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.08 vs a peer median of 2.59)higher risk: bigger price swings (beta 2.47 vs peers 0.63) and less liquidity (current ratio 1.08 vs peers 2.59)
About average: profitability
Ranks #266 of 1,157 healthcare companies (top 23%)
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Oscar Health made a profit per share in its latest year after a loss the year before.
Valuation signals disagree.Cheaper than 95% of peers on operating cash profit (EBITDA), but only 50% on free cash flow.Cheaper than 95% of peers on operating cash profit, but only 50% on free cash flow.
Relative to its operating cash profit (EBITDA), Oscar Health looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Oscar Health looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.
Cash flow well above reported profit. Free cash flow is 8.0× reported profit.
Free cash flow is 8.0× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $463M in 2020 to $11.7B in 2025.
Oscar Health's fiscal-year revenue rose in each of the five years to 2025, from $463M to $11.7B.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Oscar Health
Is Oscar Health getting weaker?
Its latest SEC filing (Aug 7, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 4.0 points to 4.1%. Its overall score is unchanged at 64/100 since Oct 28, 2026.
How is Oscar Health valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 90/100 against 1,393 healthcare peers.EBITDA yield 24.0% vs a peer median of 4.0% (stronger than 95% of peers).EBITDA yield 24.0% vs peers 4.0% (stronger than 95% of peers).
Is Oscar Health growing?
Yes, faster than most of its peers. Growth scores 92/100 against 1,393 healthcare peers.3-year revenue growth 45.6% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 45.6% vs peers 5.8% (stronger than 92% of peers).
How profitable is Oscar Health?
About as profitable as its peers. Profitability scores 56/100 against 1,393 healthcare peers.Return on assets 4.9% vs a peer median of 1.7% (stronger than 72% of peers).Return on assets 4.9% vs peers 1.7% (stronger than 72% of peers).
How risky is Oscar Health?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 2.47 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.47 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 7, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Turned profitable over the last 12 months
Operating margin rose 4.0 points to 4.1%
Previous quarter
Latest quarter
Change
Revenue (12 months)
13.3B USD
15.3B USD
+15.2%
Net income (12 months)
−39.4M USD
550.7M USD
turned positive
Operating margin
0.1%
4.1%
+4.0 pts
Free cash flow (12 months)
2.8B USD
4.4B USD
+56.5%
Debt
430.9M USD
431.6M USD
+0.2%
Cash
4.8B USD
4.1B USD
−15.2%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Healthcare Plans companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
-29.6%
-14.9%
-4.0%
0.6%
-3.4%
▼ 4.0 pts
Net margin
-31.1%
-15.3%
-4.6%
0.3%
-3.8%
▼ 4.1 pts
Return on assets (ROA)
-17.2%
-13.4%
-7.5%
0.5%
-7.0%
▼ 7.5 pts
Return on equity (ROE)
-41.3%
-68.1%
-33.7%
2.5%
-45.3%
▼ 48 pts
Debt to equity
0.00×
0.33×
0.37×
0.30×
0.44×
▲ 49%
Interest coverage
-115.36×
-26.07×
-9.58×
2.41×
-22.52×
▼ >999%
OSCR price history
Price history is added with the daily price update and will appear after the next one.